{"id":"crexont-er","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Allergic reactions (rash, urticaria)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cephalexin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. The extended-release formulation allows for less frequent dosing while maintaining therapeutic drug levels. This mechanism is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.","oneSentence":"CREXONT ER is an extended-release formulation of cephalexin, a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:27.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections caused by susceptible organisms (respiratory tract infections, skin and soft tissue infections, urinary tract infections)"}]},"trialDetails":[{"nctId":"NCT07138560","phase":"PHASE4","title":"BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-07-24","conditions":"Parkinson Disease","enrollment":22},{"nctId":"NCT06765668","phase":"PHASE4","title":"A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease","status":"RECRUITING","sponsor":"Impax Laboratories, LLC","startDate":"2025-02-12","conditions":"Parkinson Disease","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IPX203"],"phase":"marketed","status":"active","brandName":"CREXONT ER","genericName":"CREXONT ER","companyName":"Impax Laboratories, LLC","companyId":"impax-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CREXONT ER is an extended-release formulation of cephalexin, a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections caused by susceptible organisms (respiratory tract infections, skin and soft tissue infections, urinary tract infections).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}